Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine, a division of the renowned Johnson & Johnson family, is headquartered in the United States and operates extensively across major global regions, including Europe and Asia. Founded in 1886, the company has established itself as a leader in the pharmaceutical industry, focusing on innovative solutions in areas such as immunology, oncology, neuroscience, and infectious diseases. With a commitment to advancing healthcare, Johnson & Johnson Innovative Medicine offers a diverse portfolio of core products, including biologics and advanced therapies that are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including numerous FDA approvals and groundbreaking research initiatives, solidifying its position as a trusted name in the market. Through its dedication to innovation and patient care, Johnson & Johnson continues to make a profound impact on global health.
DitchCarbon Score
How does Johnson & Johnson Innovative Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Johnson & Johnson Innovative Medicine's score of 51 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Johnson & Johnson Innovative Medicine's reported carbon emissions
Johnson & Johnson Innovative Medicine, headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, nor do they outline any defined reduction targets or initiatives. Without available emissions figures, it is challenging to assess their current carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the company is expected to be engaged in industry-standard climate commitments, which typically include efforts to reduce greenhouse gas emissions and enhance sustainability practices. As part of the broader pharmaceutical industry, Johnson & Johnson Innovative Medicine may align with global climate initiatives and frameworks aimed at reducing environmental impact, although specific details on their commitments or achievements are not disclosed. In summary, while concrete emissions data and reduction targets are absent, Johnson & Johnson Innovative Medicine's involvement in climate action remains a critical aspect of their operational strategy within the pharmaceutical sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Johnson & Johnson Innovative Medicine is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
